메뉴 건너뛰기




Volumn 71, Issue 2, 2014, Pages 103-109

Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; FLUCONAZOLE; GEMFIBROZIL; GLIBENCLAMIDE PLUS METFORMIN; GLYCOSYLATED HEMOGLOBIN; INCRETIN; KETOCONAZOLE; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; WARFARIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; URACIL;

EID: 84906074064     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130131     Document Type: Review
Times cited : (11)

References (32)
  • 2
    • 43449108812 scopus 로고    scopus 로고
    • Economic costs of diabetes in the U.S. in 2007
    • American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008; 31(3):1-20.
    • (2008) Diabetes Care , vol.31 , Issue.3 , pp. 1-20
    • American Diabetes Association1
  • 3
    • 79956326006 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials
    • Esposito K, Cozzolino D, Bellastella G et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011; 13:594-603.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 594-603
    • Esposito, K.1    Cozzolino, D.2    Bellastella, G.3
  • 4
    • 79961222810 scopus 로고    scopus 로고
    • Pharmacology of dipeptidyl peptidase-4 inhibitors, similarities and differences
    • Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors, similarities and differences. Drugs. 2011; 71:1441-67.
    • (2011) Drugs , vol.71 , pp. 1441-1467
    • Baetta, R.1    Corsini, A.2
  • 5
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364-79.
    • (2012) Diabetes Care , vol.35 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 7
    • 84862645734 scopus 로고    scopus 로고
    • Alogliptin as an initial therapy in patients with newly diagnosed, drug naive type 2 diabetes: A randomized, control trial
    • Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naive type 2 diabetes: a randomized, control trial. Endocrine. 2012; 41:435-41.
    • (2012) Endocrine , vol.41 , pp. 435-441
    • Kutoh, E.1    Ukai, Y.2
  • 8
    • 84863436536 scopus 로고    scopus 로고
    • Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
    • Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012; 51:501-14
    • (2012) Clin Pharmacokinet , vol.51 , pp. 501-514
    • Golightly, L.K.1    Drayna, C.C.2    McDermott, M.T.3
  • 9
    • 79952383225 scopus 로고    scopus 로고
    • Pharmacological and clinical profile of alogliptin benzoate (NESINA)
    • In Japanese
    • Takeuchi K, Fujita T, Hiroi S. [Pharmacological and clinical profile of alogliptin benzoate (NESINA)]. Nihon Yakurigaku Zasshi. 2011; 137:43-50. In Japanese.
    • (2011) Nihon Yakurigaku Zasshi , vol.137 , pp. 43-50
    • Takeuchi, K.1    Fujita, T.2    Hiroi, S.3
  • 10
    • 77957696165 scopus 로고    scopus 로고
    • Alogliptin: A review of its use in the management of type 2 diabetes mellitus
    • Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010; 70:2051-72.
    • (2010) Drugs , vol.70 , pp. 2051-2072
    • Scott, L.J.1
  • 11
    • 67651173077 scopus 로고    scopus 로고
    • Incretin-based therapies for type 2 diabetes mellitus
    • Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009; 5:262-9.
    • (2009) Nat Rev Endocrinol , vol.5 , pp. 262-269
    • Lovshin, J.A.1    Drucker, D.J.2
  • 12
    • 58149171060 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control
    • DeFronzo RA, Fleck PR, Wilson CA et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care. 2008; 31:2315-7.
    • (2008) Diabetes Care , vol.31 , pp. 2315-2317
    • DeFronzo, R.A.1    Fleck, P.R.2    Wilson, C.A.3
  • 13
    • 84867136387 scopus 로고    scopus 로고
    • Natiuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
    • Rieg T, Gerasimova M, Murray F et al. Natiuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol. 2012; 303:F963-71.
    • (2012) Am J Physiol Renal Physiol , vol.303 , pp. F963-F971
    • Rieg, T.1    Gerasimova, M.2    Murray, F.3
  • 14
    • 65649116135 scopus 로고    scopus 로고
    • Alogliptin: A new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    • Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2009; 10:503-12.
    • (2009) Expert Opin Pharmacother , vol.10 , pp. 503-512
    • Pratley, R.E.1
  • 15
    • 73649128872 scopus 로고    scopus 로고
    • Pharmacokinetics of alogliptin when administered with food, metformin or cimetidine; a two-phase, crossover study in healthy subjects
    • Karim A, Covington P, Christopher R et al. Pharmacokinetics of alogliptin when administered with food, metformin or cimetidine; a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2010; 48:46-58.
    • (2010) Int J Clin Pharmacol Ther , vol.48 , pp. 46-58
    • Karim, A.1    Covington, P.2    Christopher, R.3
  • 16
    • 41649102998 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl-4 inhibitor alogliptin in male subjects
    • Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl-4 inhibitor alogliptin in male subjects. Clin Ther. 2008; 30:513-27.
    • (2008) Clin Ther , vol.30 , pp. 513-527
    • Christopher, R.1    Covington, P.2    Davenport, M.3
  • 17
    • 70549085872 scopus 로고    scopus 로고
    • Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes
    • Christopher R, Karim A. Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol. 2009; 2:589-600.
    • (2009) Expert Rev Clin Pharmacol , vol.2 , pp. 589-600
    • Christopher, R.1    Karim, A.2
  • 18
    • 41649083174 scopus 로고    scopus 로고
    • Pharmacokinetic, pharmacodynamics, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, controlled, double-blind, placebo-controlled, multiple dose study in adult patients with type 2 diabetes
    • Covington P, Christopher R, Davenport M et al. Pharmacokinetic, pharmacodynamics, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, controlled, double-blind, placebo-controlled, multiple dose study in adult patients with type 2 diabetes. Clin Ther. 2008; 30:499-512.
    • (2008) Clin Ther , vol.30 , pp. 499-512
    • Covington, P.1    Christopher, R.2    Davenport, M.3
  • 19
    • 67649360705 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects
    • Abstract
    • Hirayama M, Matsuno K, Fujita T et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects. Diabetes. 2008; 57(suppl 1):A155. Abstract.
    • (2008) Diabetes , vol.57 , pp. A155
    • Hirayama, M.1    Matsuno, K.2    Fujita, T.3
  • 20
    • 67649337808 scopus 로고    scopus 로고
    • Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment
    • Abstract
    • Karim A, Fleck P, Hetman L et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Diabetes. 2008; 57(suppl 1):A160. Abstract.
    • (2008) Diabetes , vol.57 , pp. A160
    • Karim, A.1    Fleck, P.2    Hetman, L.3
  • 21
    • 77955456705 scopus 로고    scopus 로고
    • Pharmacokinetics of dipeptidyl peptidase-4 inhibitors
    • Scheen AJ. Pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2010; 12:648-58.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 648-658
    • Scheen, A.J.1
  • 22
    • 70349510604 scopus 로고    scopus 로고
    • Coadministration of pioglitazone or glyburide and alogliptin: Pharmacokinetic drug interaction assessment in healthy participants
    • Karim A, Laurent A, Munsaka M et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009; 49:1210-9.
    • (2009) J Clin Pharmacol , vol.49 , pp. 1210-1219
    • Karim, A.1    Laurent, A.2    Munsaka, M.3
  • 23
    • 79951699944 scopus 로고    scopus 로고
    • Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes
    • Rosenstock J, Inzucchi SR, Seufert J et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010; 33:2406-8.
    • (2010) Diabetes Care , vol.33 , pp. 2406-2408
    • Rosenstock, J.1    Inzucchi, S.R.2    Seufert, J.3
  • 24
    • 57649225147 scopus 로고    scopus 로고
    • Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A multicenter, randomized, double-blind, placebo-controlled study
    • Nauck MA, Ellis GC, Fleck PR et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, double-blind, placebo-controlled study. Int J Clin Pract. 2009; 63:46-55.
    • (2009) Int J Clin Pract , vol.63 , pp. 46-55
    • Nauck, M.A.1    Ellis, G.C.2    Fleck, P.R.3
  • 25
    • 80055037047 scopus 로고    scopus 로고
    • Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate control on metformin and pioglitazone: A 52-week, randomized, double-blind, active-controlled, parallel-group study
    • Bosi E, Ellis GC, Wilson CA et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011; 13:1088-96.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 1088-1096
    • Bosi, E.1    Ellis, G.C.2    Wilson, C.A.3
  • 26
    • 70450173642 scopus 로고    scopus 로고
    • Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
    • Rosenstock J, Rendell MS, Gross JL et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009; 11:1145-52.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 1145-1152
    • Rosenstock, J.1    Rendell, M.S.2    Gross, J.L.3
  • 27
    • 84903893337 scopus 로고    scopus 로고
    • Deerfield, IL: Takeda Pharmaceuticals America
    • Nesina (alogliptin) package insert. Deerfield, IL: Takeda Pharmaceuticals America; 2013.
    • (2013) Nesina (Alogliptin) Package Insert
  • 30
    • 79959559653 scopus 로고    scopus 로고
    • Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1-based therapies
    • Elashoff M, Matveyenko AV, Gier B et al. Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141:150-6.
    • (2011) Gastroenterology , vol.141 , pp. 150-156
    • Elashoff, M.1    Matveyenko, A.V.2    Gier, B.3
  • 31
    • 84907272031 scopus 로고    scopus 로고
    • Greenwood Village, CO: Truven Health Analytics. Updated periodically
    • Red book database. Greenwood Village, CO: Truven Health Analytics. Updated periodically.
    • Red Book Database
  • 32
    • 84857343528 scopus 로고    scopus 로고
    • Alogliptin benzoate for the treatment of type 2 diabetes
    • Rendell M, Drincic A, Andukuri R. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012; 13:553-63.
    • (2012) Expert Opin Pharmacother , vol.13 , pp. 553-563
    • Rendell, M.1    Drincic, A.2    Andukuri, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.